PMID- 31514790
OWN - NLM
STAT- MEDLINE
DCOM- 20200714
LR  - 20200714
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 40
IP  - 5
DP  - 2019 Sep 1
TI  - Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory 
      disease.
PG  - 316-320
LID - 10.2500/aap.2019.40.4241 [doi]
AB  - Background: The current treatment for patients with aspirin-exacerbated 
      respiratory disease (AERD) who have uncontrolled asthma or chronic rhinosinusitis 
      is aspirin desensitization. For patients who are unable to undergo or do not 
      benefit from aspirin desensitization, treatment with biologics is an option, 
      although efficacy data for AERD is scarce. Objective: We reported a series of 
      patients with AERD who were started on omalizumab and measured the outcomes to 
      assess improvement. Methods: Adult patients with AERD who were initiated on 
      omalizumab from January 2007 to January 2018 were included. We compared outcomes 
      6-12 months before initiating biologic therapy and during the last 6-12 months 
      while they were on biologic therapy. Our study investigated the number of oral 
      steroid courses, short-acting beta-agonists (SABA), antibiotics for sinusitis or 
      pneumonia, emergency department visits, hospitalizations, pulmonary function 
      tests, and changes in controller medications. Results: Twenty-nine patients were 
      placed on omalizumab. Sixty-two percent demonstrated a reduction in the number of 
      steroid courses (p = 0.0014) and number of SABA canisters used (p = 0.0005) 
      during their last 12 months while on omalizumab. Eighty-six percent of the 
      patients with AERD and on omalizumab demonstrated either a decrease in the number 
      of steroid courses or number of SABA canisters used in the last year of the 
      study. The patients with AERD and with concomitant immunoglobulin E (IgE) 
      mediated respiratory disease showed a statistically significant reduction in the 
      number of steroid courses and number of SABA canisters used while on omalizumab 
      for 1 year (p = 0.002 and p = 0.005, respectively), whereas those without 
      concomitant IgE-mediated respiratory disease did not have a substantial reduction 
      in steroids or SABA canisters used. Conclusion: Our case series reported that 
      omalizumab could effectively be used as an adjunct treatment for AERD, but 
      additional larger and longitudinal studies are needed to corroborate these 
      findings.
FAU - Jean, Tiffany
AU  - Jean T
AD  - From the Department of Allergy and Immunology, Kaiser Permanente Los Angeles 
      Medical Center, Los Angeles, California.
FAU - Eng, Victoria
AU  - Eng V
AD  - From the Department of Allergy and Immunology, Kaiser Permanente Los Angeles 
      Medical Center, Los Angeles, California.
FAU - Sheikh, Javed
AU  - Sheikh J
AD  - From the Department of Allergy and Immunology, Kaiser Permanente Los Angeles 
      Medical Center, Los Angeles, California.
FAU - Kaplan, Michael S
AU  - Kaplan MS
AD  - From the Department of Allergy and Immunology, Kaiser Permanente Los Angeles 
      Medical Center, Los Angeles, California.
FAU - Goldberg, Bruce
AU  - Goldberg B
AD  - From the Department of Allergy and Immunology, Kaiser Permanente Los Angeles 
      Medical Center, Los Angeles, California.
FAU - Jau Yang, Su
AU  - Jau Yang S
AD  - Department of Research and Evaluation, Kaiser Permanente, Pasadena, California.
FAU - Samant, Shefali
AU  - Samant S
AD  - From the Department of Allergy and Immunology, Kaiser Permanente Los Angeles 
      Medical Center, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Steroids)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Allergic Agents/pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects
MH  - Asthma, Aspirin-Induced/*drug therapy
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Immunoglobulin E/drug effects
MH  - Male
MH  - Middle Aged
MH  - Omalizumab/*pharmacology/therapeutic use
MH  - Respiration Disorders/chemically induced/drug therapy
MH  - Steroids/therapeutic use
MH  - Treatment Outcome
EDAT- 2019/09/14 06:00
MHDA- 2020/07/15 06:00
CRDT- 2019/09/14 06:00
PHST- 2019/09/14 06:00 [entrez]
PHST- 2019/09/14 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
AID - 10.2500/aap.2019.40.4241 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2019 Sep 1;40(5):316-320. doi: 10.2500/aap.2019.40.4241.